Stemcell Technologies Articles & Analysis: Older
26 news found
We are excited to announce that Gustav Mahler is hired as the Chief Executive Officer of Ncardia and Cellistic and will join the Board of Directors. Our founder Stefan Braam will assume the role of President and Chief Technical Officer and will remain in the board of directors. With this shift in our leadership team, we hope to continue our journey of rapid growth and expansion delivering world ...
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced positive two-year follow-up data for the Company's StemSpine® pilot study, showing significant efficacy of the StemSpine® ...
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced positive three-year follow up data for the Company's OvaStem® pilot study. The data shows significant efficacy of the OvaStem® ...
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced that the Company has signed an agreement with Greenstone Biosciences Inc. in Palo Alto, CA for the development of a human induced ...
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced that it has entered into a securities purchase agreement with several institutional investors to purchase 7,555,556 shares of common ...
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced progress in developing a reproducible clinical grade product of ImmCelz®. Multiple clinical experiments were performed in which the ...
Ncardia has launched a new business, Cellistic to focus Ncardia’s induced pluripotent stem cell (iPSC) expertise on the cell therapy development and manufacturing sector. This strategy expands on Ncardia’s existing drug discovery solutions business and capitalizes on the company’s deep expertise in iPSC differentiation and expansion to focus dedicated resources and capabilities ...
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced that it has signed a Master Collaboration Agreement with the University of Miami to accelerate development of the Company's ImmCelz® ...
Stemedica Cell Technologies, Inc. (“Stemedica”), a San Diego-based biotech company specializing in the manufacture of clinical grade stem cells, announced today that it has appointed Darius Anderson, a veteran business executive and one of the state of California’s most respected entrepreneurs and political strategists, to its Board of Directors. “We are fortunate to have ...
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced that it has signed an agreement with Cervos Inc. ("Cervos Medical") to become the exclusive distributor of Marrow Cellution™ ...
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced that Company executives will be participating in the 34th Annual Roth Conference to be held March 13-15, 2022 in Dana Point, California. ...
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced the appointment of Sahil Nock as the Company's Chief Commercial Officer, effective February 28, 2022. Mr. Nock brings to Creative ...
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV:HEM; OTCQB:HMTXF; FSE:2VFO) is pleased to announce it has signed a contract with Dr. James Shapiro, University of Alberta, Edmonton and will complete a transfer ACP-01 to Dr. Shapiro’s laboratory. The combination of ACP-01, an autologous angiogenic cell precursor that has demonstrated improvement of angiogenesis ...
Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Cato T. Laurencin, M.D., Ph.D., to the company's Board of Directors. Dr. Laurencin is a distinguished university professor, award-winning engineer, orthopaedic surgeon, scientist, administrator, and pioneer in the field of regenerative engineering. Dr. Laurencin is actively involved in mentoring and social ...
ByAlkermes
BlueRock Therapeutics LP, a leading engineered cell therapy company and a wholly-owned and independently operated subsidiary of Bayer AG, and Senti Biosciences, Inc. (Senti Bio), a leading gene circuit company, today announced a collaboration and option agreement to apply Senti Bio’s gene circuit technology to the development of BlueRock’s next-generation engineered cell ...
Stemedica Cell Technologies, Inc. (“Stemedica”), a San Diego-based biotech company specializing in the manufacture of clinical grade stem cells, announced today that it has signed a Licensing Agreement with Pulthera, LLC for the rights to use, distribute and sell its mesenchymal stem cell technologies in the treatment of COVID-19 and additional pulmonary conditions. The agreement was ...
BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, FUJIFILM Cellular Dynamics, Inc. a leading global developer and manufacturer of human induced pluripotent stem (iPS) cell technologies, and Opsis Therapeutics, LLC, a joint venture of FUJIFILM Cellular Dynamics (FCDI) and David Gamm, M.D., Ph.D., co-founder, focusing on developing cell ...
BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, FUJIFILM Cellular Dynamics, Inc. a leading global developer and manufacturer of human induced pluripotent stem (iPS) cell technologies, and Opsis Therapeutics, LLC, a joint venture of FUJIFILM Cellular Dynamics (FCDI) and David Gamm, M.D., Ph.D., co-founder, focusing on developing cell ...
Modena, 23 April 2021 – The European Research Council (ERC) yesterday announced the winners of the 2020 Advanced Grants. The grants, worth a total of €507 million, will support 209 researchers across Europe. Eight projects were won by researchers working in Italy, including the project presented by Michele De Luca, Director of the “Stefano Ferrari” Centre for Regenerative ...
Ncardia and BlueRock Therapeutics today announced an agreement covering process development technologies for the manufacture of induced pluripotent stem cell (iPSC)-derived cardiomyocytes. Under the terms of the agreement, Bluerock gains access to Ncardia’s large-scale production processes and intellectual property for the production of iPSC-derived cardiomyocytes for therapeutic use. ...